Oxaliplatin induces a delayed immune-mediated hemolytic anemia: a case report and review of the literature.
We report a case of a 59-year-old woman with metastatic carcinoma of the ileocecal region who received FOLFOX(oxaliplatin/leucovorin/5-fluorouracil) and bevacizumab therapy and exhibited a partial remission with minimal side effects. She developed a mild self-limited episode of immune-mediated hemolytic anemia during her 16th cycle of chemotherapy, which precluded her from receiving further oxaliplatin. We review the literature on oxaliplatin-induced immune-mediated hemolysis, including its mechanism, presenting symptoms, laboratory features, management, and implications for future therapy.
Noronha
Vanita
V
Mid Valley Oncology/Hematology, P.C., 407 Gidney Avenue, Newburgh, NY 12550, USA. vanita.noronha@gmail.com
Burtness
Barbara
B
Murren
John
J
Duffy
Thomas P
TP
D000743:Anemia, Hemolytic / Q000139:chemically induced*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D002430:Cecal Neoplasms / Q000188:drug therapy; D004342:Drug Hypersensitivity / Q000209:etiology*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000139:chemically induced*; D007078:Ileal Neoplasms / Q000188:drug therapy; D007414:Intestinal Neoplasms / Q000188:drug therapy*; D002955:Leucovorin / Q000627:therapeutic use; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D000077150:Oxaliplatin; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil